Biotech Startups

Moleculent develops biological discovery and disease understanding tools for scientists. The company focuses on decoding molecular foundations of biology to advance human health diagnostics and research.

2 investors

MONCYTE Health develops a personalized diagnostic test that helps clinicians choose more effective cholesterol-lowering treatments for patients with high cholesterol. The test is aimed at optimizing treatment and prevention of cardiovascular disease.

2 investors

ClinLife operates an online portal that matches patients with clinical trials suited to their health profile, guiding them through questionnaires and a medical team to find suitable studies. The service is available in over 50 countries and 35 languages, and also helps trial organizers reach eligible patients.

2 investors

Monod Bio is a University of Washington spin-out that uses AI-powered de novo protein design to develop research-use-only tools and in vitro diagnostics. It operates in the life sciences and medical diagnostics sector.

2 investors

Monteris develops minimally invasive laser ablation technology (LITT) used to treat brain conditions including oncology tumors and drug-resistant epilepsy. It focuses on generating prospective multi-center clinical evidence to support physicians treating these patients.

2 investors

Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome. It also has a second program inhibiting CD93 for lung squamous cell carcinoma.

2 investors

Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma. The biotech company is based near Leuven, Belgium.

2 investors

Developer of a microneedle-based peanut allergy treatment (MOON101)

2 investors

Moonlight Therapeutics is a clinical-stage biotech company developing an intradermal stamp-based immunotherapy for people with food allergies. Its lead therapy, MOON101, targets peanut allergy.

2 investors

Morus Inc. is a Japanese company established in April 2021 and led by CEO Ryo Sato. The page provides only corporate registration details and does not describe the company's products or services.

2 investors

Motley Bio is a Silicon Valley company applying multiomics analysis to the study of disease at early stages. Its work is directed at identifying the biological changes that precede clinical symptoms, for use in research and diagnostics.

2 investors

MRM Health develops microbiome-based therapeutics using a precision-engineered platform called CORAL®, which designs and manufactures live bacterial consortia to treat diseases caused by microbiome dysbiosis. The company serves patients and pharmaceutical partners seeking novel disease-modifying treatments grounded in microbiome science.

2 investors

Mycophyto develops biological solutions that leverage mycorrhizal fungi symbiosis with plants to enhance water uptake, nutrient access, and stress resistance, promoting sustainable and resilient agricultural production.

2 investors

Myosin Therapeutics is a clinical-stage biotechnology company developing a new class of targeted therapies that act on molecular nanomotors such as nonmuscle myosin II to treat cancer and neurological diseases. Its approach targets the physical mechanics of cells driving tumor progression and brain plasticity, with programs including MT-110 and MT-125 for oncology and CNS indications.

2 investors

myTomorrows operates an online platform and patient navigation service that helps patients and their physicians discover and access clinical trials, expanded access programs, and treatments in development. It connects patients, treating physicians, and BioPharma research teams, supporting patient recruitment, expanded access management, and real-world data collection.

2 investors

Nanite develops resorbable polymer nanoparticles (PNPs) for virus-free genetic drug delivery, using high-throughput synthesis and AI to design precision delivery vectors for gene therapy. It targets subcutaneous gene therapy as an alternative to viral vectors and lipid nanoparticles.

2 investors

Nanobots Therapeutics develops the MotionTx platform to create nanobots that penetrate tissues and enhance drug accumulation in target cells for therapeutic applications. The company is a spin-off of ICREA and IBEC resulting from research by Prof. Samuel Sánchez.

2 investors

NanoCarry is developing a proprietary drug-delivery technology platform designed to move therapeutic antibodies across the blood-brain barrier for the treatment of brain cancers and central nervous system diseases. The platform uses a "Plug & Play" approach aimed at substantially increasing the brain delivery of injected antibody doses.

2 investors

Nanocrine develops nanoplasmonic biosensor chips that let cell biology researchers image protein secretions from living cells in real time, without labels, using standard live-cell microscopes. Its single-use biochips apply surface plasmon resonance sensing to map extracellular secretions spatially, functioning like a real-time, microscope-based ELISA.

2 investors

Technology to unlock the human proteome.

2 investors

Nanophage Technologies develops biological nanorod scaffolds for diagnostic assay applications, enabling enhanced detection and sensitivity in clinical and research settings. The company serves diagnostics manufacturers, pharmaceutical discovery organizations, and clinical laboratories.

2 investors

Nano PharmaSolutions develops NanoTransformer, a patented nanodrug manufacturing platform that improves drug solubility and bioavailability, and delivery systems such as Nano-CNS for neurotherapeutics via nasal spray. The company applies its technology to drug-device combination products for the pharmaceutical industry.

2 investors

NanoPhoria is a life sciences company that raised an €83.5 million Series A round. The page focuses on its investors and does not detail its specific product or technology.

2 investors

Oxford Nanopore offers educational programs and tools to make DNA sequencing accessible to students and educators from high school through undergraduate levels. The company works with institutions and scientific educators to integrate nanopore sequencing technology into classroom settings and address the world's pressing challenges.

2 investors